Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM96SE0)

Drug Name
Haloperidol Drug Info
Synonyms
Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]
Therapeutic ClassAntipsychotic Agents
Cross-matching ID
PubChem CID
3559
ChEBI ID
CHEMBL54
CAS Number
CAS 52-86-8
TTD Drug ID
D0D1AL
VARIDT Drug ID
DR00426
INTEDE Drug ID
DR0801
ACDINA Drug ID
D00310

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.47 0.00e+0 19/20 (95%) MSMO1;SQLE;DHCR24;...
Terpenoid backbone biosynthesis 2.36 0.00e+0 18/22 (81.82%) HMGCS1;ACAT2;IDI1;...
Biosynthesis of unsaturated fatty acids 2.14 0.00e+0 21/27 (77.78%) SCD;ELOVL2;FADS1;...
Metabolism of xenobiotics by cytochrome P450 2.12 0.00e+0 49/77 (63.64%) ADH1B;ADH1C;UGT2B4;...
Drug metabolism 2.12 0.00e+0 78/151 (51.66%) FMO3;ADH1B;ADH1C;...
Cholesterol metabolism 2.12 0.00e+0 44/50 (88%) LDLR;NPC2;LIPG;...
Retinol metabolism 2.09 0.00e+0 41/68 (60.29%) ADH1B;ADH1C;UGT2B4;...
Butanoate metabolism 2.07 0.00e+0 23/28 (82.14%) HMGCS1;ACAT2;ACAT1;...
Synthesis and degradation of ketone bodies 2.06 0.00e+0 9/10 (90%) HMGCS1;ACAT2;ACAT1;...
Peroxisome 2.05 0.00e+0 72/82 (87.8%) ACOX2;PIPOX;PXMP2;...
Valine, leucine and isoleucine degradation 2.03 0.00e+0 42/48 (87.5%) HMGCS1;ACAT2;ACAT1;...
PPAR signaling pathway 1.99 5.16e-4 66/74 (89.19%) HMGCS1;SCD;FADS2;...
Spliceosome 1.98 4.76e-4 101/150 (67.33%) PUF60;SNRPB2;PRPF4;...
Fatty acid degradation 1.97 4.42e-4 40/43 (93.02%) ACAT2;ADH1B;ADH1C;...
DNA replication 1.96 8.26e-4 34/36 (94.44%) PCNA;POLE2;RFC5;...
Complement and coagulation cascades 1.93 7.74e-4 76/85 (89.41%) CFI;SERPINB2;TFPI;...
Tyrosine metabolism 1.88 1.09e-3 30/36 (83.33%) TYRP1;ADH1B;ADH1C;...
Mismatch repair 1.87 1.03e-3 22/23 (95.65%) PCNA;RFC5;MLH1;...
Pyruvate metabolism 1.82 2.93e-3 41/47 (87.23%) ACAT2;ADH1B;ADH1C;...
Base excision repair 1.81 2.79e-3 29/33 (87.88%) PCNA;POLE2;HMGB1;...
Homologous recombination 1.79 3.54e-3 35/41 (85.37%) BARD1;MRE11;BRCA1;...
Nucleotide excision repair 1.78 4.22e-3 40/47 (85.11%) PCNA;RAD23B;POLE2;...
Primary bile acid biosynthesis 1.74 5.92e-3 15/17 (88.24%) ACOX2;CYP27A1;SCP2;...
Cell cycle 1.72 8.52e-3 110/124 (88.71%) CDC20;PLK1;PCNA;...
Propanoate metabolism 1.71 9.17e-3 30/34 (88.24%) ACAT2;ACAT1;EHHADH;...
Oxidative phosphorylation 1.69 1.26e-2 93/133 (69.92%) ATP6V1H;ATP5MC2;ATP6V1D;...
Fatty acid elongation 1.66 1.70e-2 19/27 (70.37%) ELOVL2;ELOVL6;TECR;...
Glyoxylate and dicarboxylate metabolism 1.65 1.86e-2 23/30 (76.67%) ACAT2;GLUL;ACAT1;...
Steroid hormone biosynthesis 1.60 2.71e-2 43/61 (70.49%) HSD17B7;UGT2B4;HSD11B1;...
Non-homologous end-joining 1.57 3.44e-2 11/13 (84.62%) DNTT;MRE11;XRCC5;...
Fc epsilon RI signaling pathway -1.69 1.82e-2 57/68 (83.82%) PIK3CB;LCP2;PDPK1;...
Cholinergic synapse -1.70 1.75e-2 99/113 (87.61%) PIK3CD;KCNJ4;KCNJ6;...
Rap1 signaling pathway -1.70 1.81e-2 184/210 (87.62%) RAC3;RAPGEF4;RRAS;...
Dilated cardiomyopathy -1.73 1.25e-2 86/96 (89.58%) ITGA9;ITGA8;DMD;...
Chronic myeloid leukemia -1.74 1.14e-2 72/76 (94.74%) TGFB2;GAB2;TGFB3;...
FoxO signaling pathway -1.75 1.01e-2 118/131 (90.08%) RBL2;FASLG;GADD45B;...
Hippo signaling pathway -1.76 8.81e-3 120/186 (64.52%) DLG3;PPP1CC;NF2;...
MAPK signaling pathway -1.76 8.58e-3 272/294 (92.52%) MAP4K4;NFATC1;TAB1;...
TNF signaling pathway -1.76 8.97e-3 103/112 (91.96%) TAB1;CASP3;MMP14;...
ErbB signaling pathway -1.77 8.72e-3 79/85 (92.94%) PAK2;PIK3CD;SRC;...
Proteoglycans in cancer -1.77 9.16e-3 172/205 (83.9%) CASP3;FZD10;CD63;...
Allograft rejection -1.80 6.67e-3 32/38 (84.21%) FASLG;CD86;HLA-DRB1;...
Autoimmune thyroid disease -1.81 5.48e-3 46/53 (86.79%) FASLG;CD86;HLA-DRB1;...
Choline metabolism in cancer -1.82 4.97e-3 84/98 (85.71%) MAPK8;DGKG;RAF1;...
Insulin secretion -1.83 5.28e-3 75/86 (87.21%) ADCY1;PRKACB;ADCY9;...
Notch signaling pathway -1.83 4.70e-3 49/59 (83.05%) ATXN1;EP300;DLL3;...
Relaxin signaling pathway -1.83 5.03e-3 114/129 (88.37%) PIK3CD;SRC;GNG10;...
Type II diabetes mellitus -1.83 5.42e-3 42/46 (91.3%) ADIPOQ;INS;PIK3CD;...
Central carbon metabolism in cancer -1.83 5.87e-3 67/70 (95.71%) KIT;MYC;HRAS;...
Type I diabetes mellitus -1.85 5.12e-3 38/43 (88.37%) GAD1;GAD2;HLA-DPB1;...
Parathyroid hormone synthesis, secretion and action -1.85 5.64e-3 98/106 (92.45%) MMP14;RAF1;MMP25;...
Focal adhesion -1.88 6.26e-3 180/201 (89.55%) ITGA9;ROCK1;ITGA8;...
Prostate cancer -1.92 1.76e-3 93/97 (95.88%) EP300;INS;CDK2;...
Viral myocarditis -1.95 2.01e-3 53/60 (88.33%) RAC3;HLA-DPB1;HLA-DOA;...
Glucagon signaling pathway -1.95 2.35e-3 89/107 (83.18%) PPP3CB;PRKACB;PGAM1;...
Insulin signaling pathway -1.97 2.82e-3 121/137 (88.32%) PHKA2;HK1;MAPK8;...
Growth hormone synthesis, secretion and action -1.97 3.52e-3 108/119 (90.76%) MAPK8;RAF1;ADCY1;...
Graft-versus-host disease -1.98 4.70e-3 32/42 (76.19%) FASLG;CD86;HLA-DRB1;...
Protein digestion and absorption -2.00 7.05e-3 78/103 (75.73%) SLC8A2;CTRB2;COL6A1;...
Asthma -2.05 1.41e-2 25/31 (80.65%) HLA-DRB1;HLA-DOB;HLA-DRA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H